HER2 targeted therapy is a newly developed method to treat HER2 positive tumors in recent years, such as breast cancer (Hackshaw et al., 2020), gastric cancer, and esophageal cancer (Gerson et al., 2017), with obvious effects. The gene discussed is ERBB2; the disease is esophageal cancer.